Sunshine Biopharma- Warrants (15/02/2027) Operating Income

As of the most recent data (June 2026), SBFMW shows a operating income of $-5.8M. That compares with $-6.5M in the prior-year period — up 12.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBFMW's operating income is now $-5.8M (was $-6.5M) — a 12.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sunshine Biopharma- Warrants (15/02/2027) is outperforming or lagging.

Tracking SBFMW's operating income over time shows whether Sunshine Biopharma- Warrants (15/02/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $-5.8M That compares with $-6.5M in the prior-year period — up 12.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Sunshine Biopharma- Warrants (15/02/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-5.8M) with ownership activity and broader fundamentals.

Sunshine Biopharma- Warrants (15/02/2027)'s operating income is $-5.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.